Search results
Showing 1 to 7 of 7 results for darbepoetin alfa
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.
In development [GID-TA10877] Expected publication date: 20 November 2024
Anaemia (cancer-treatment induced) - Erythropoetin (alpha and beta) and darbepoetin 2 June 2006 TA143 Ankylosing spondylitis -...
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development [GID-TA10886] Expected publication date: TBC
Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)
This guidance has been replaced by NICE technology appraisal guidance 323.
ESAs in children with anaemia of chronic kidney disease (CKD) (including darbepoetin, which is currently not licensed for use in...